Commitments and Contingencies (Details)		12 Months Ended
		Dec. 31, 2017 USD ($) Complaint	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Operating Leases [Abstract]
2018	[1]	$ 373,000
2019	[1]	278,000
2020	[1]	59,000
2021	[1]	0
2022	[1]	0
Thereafter	[1]	0
Total	[1]	710,000
Employment Agreements [Abstract]
2018	[2]	1,678,000
2019	[2]	1,057,000
2020	[2]	1,057,000
2021	[2]	1,057,000
2022	[2]	0
Thereafter	[2]	0
Total	[2]	4,849,000
Research and Development [Abstract]
2018	[3]	1,000,000
2019	[3]	0
2020	[3]	0
2021	[3]	0
2022	[3]	0
Thereafter	[3]	0
Total	[3]	1,000,000
Total [Abstract]
2018		3,051,000
2019		1,335,000
2020		1,116,000
2021		1,057,000
2022		0
Thereafter		0
Total		6,559,000
Lease expense		420,106	$ 358,247	$ 351,075
Loss Contingencies [Line Items]
Potential future payments		7,500,000
Issuance of common stock		$ 28,037	$ 18,553
Number of competing derivative complaints | Complaint		2
Litigation setttlements		$ 6,500,000
Aldoxorubicin [Member]
Loss Contingencies [Line Items]
Issuance of common stock		$ 18,300,000

[1] Operating leases are primarily facility lease related obligations, as well as equipment lease obligations with third party vendors. The Company recognized rent expenses of $420,106, $358,247, and $351,075 in 2017, 2016 and 2015, respectively.

[2] Employment agreements include management contracts which have been revised from time to time. The employment agreement for the Company's executive officers provide for minimum salaries, which are adjusted annually at the discretion of the Company's Compensation Committee, and in some cases provide for minimum annual bonuses and employee benefits, as well. New employment agreements for the Company's other executive officers are usually entered into annually or biennially.

[3] Research and development obligations relate primarily to the Reimbursement Agreement with NantCell. All of these purchase obligations are cancelable.